Clinical trial

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-06-21

PhasePHASE2

Study timeline

Study start (actual)2018-06-21Date precision: day

Registry last updated2026-04-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

ApalutamideDRUG · verified · RxNorm: apalutamide

Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate

PrednisoneDRUG · verified · RxNorm: prednisone

GnRH agonist/antagonistDRUG

Sponsors & collaborators

Memorial Sloan Kettering Cancer Centerlead sponsor

Dana-Farber Cancer Institutecollaborator

Mapped research locations

New YorkNew York, United States1 BostonMassachusetts, United States1 ChicagoIllinois, United States1 ClevelandOhio, United States1 EvanstonIllinois, United States1 CommackNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03436654 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.